Alkermes (ALKS)

Company Description

Alkermes plc is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to develop innovative medicines that improve patient outcomes. The company has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Georgia and Wilmington, Ohio.

 

COMPANY ADDRESS
852 Winter Street
Waltham, MA 02451
United States

COMPANY PHONE
781-609-6000

COMPANY WEBSITE


Get BioInvest's perspective on Alkermes' CEO

Latest Company News

Analyst Activity – Cantor Fitzgerald Reiterates Neutral on Alkermes PLC ... Market Exclusive - Feb 16, 2017 The current consensus rating on Alkermes PLC (NASDAQ:ALKS) is Buy (Score: 2.70) with a consensus target price of $61.36 per share, a potential 7.86% upside. Alkermes plc (ALKS): Looking to 2018 - Cantor Fitzgerald - StreetInsider.com Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat - Yahoo Finance [...]
Thu, Feb 16, 2017 6:55:00 PM, Continue reading at the source
Alkermes Plc (ALKS) Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 15, 2017 Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today. Alkermes plc (ALKS) Tops Q4 EPS by 11c - StreetInsider.com Alkermes plc (ALKS) Moves Higher on Volume Spike for February 14 - Equities.com [...]
Wed, Feb 15, 2017 6:10:00 PM, Continue reading at the source
Alkermes plc (ALKS) Moves Higher on Volume Spike for February 10 Equities.com - Feb 10, 2017 Alkermes plc (ALKS) traded on unusually high volume on Feb. 10, as the stock gained 1.18% to close at $55.11. On the day, Alkermes plc saw 1.16 million shares trade hands on 7,544 trades. Considering that the stock averages only a daily volume of ... The 8000 Shares in Alkermes PLC (ALKS) Acquired by Sicart Associates LLC - DailyQuint [...]
Fri, Feb 10, 2017 10:30:00 PM, Continue reading at the source
Form 4 Alkermes plc. For: Feb 17 Filed by: Gaffin David Joseph StreetInsider.com - Dec 24, 2016 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person *. Gaffin David Joseph. (Last), (First), (Middle). 852 WINTER STREET. (Street). WALTHAM, MA ... [...]
Sat, Dec 24, 2016 8:48:00 AM, Continue reading at the source
Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward Motley Fool - Nov 7, 2016 Alkermes (NASDAQ:ALKS), a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline. [...]
Mon, Nov 07, 2016 7:41:00 PM, Continue reading at the source
Why Alkermes PLC Skyrocketed Today Motley Fool - Oct 21, 2016 Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo. Credit Suisse Bullish on Alkermes Plc (ALKS) as It Takes a Leap FORWARD - Smarter Analyst Alkermes Surge by a Record 47% on Depression Pill Trial Success - Bloomberg [...]
Fri, Oct 21, 2016 5:26:00 PM, Continue reading at the source
Analyst Upgrades: Alkermes Plc, Chesapeake Energy Corporation, and Paypal ... Schaeffers Research (blog) - Oct 21, 2016 Analysts are weighing in on biotech Alkermes Plc (NASDAQ:ALKS), natural gas producer Chesapeake Energy Corporation (NYSE:CHK), and digital payments stock Paypal Holdings Inc (NASDAQ:PYPL). [...]
Fri, Oct 21, 2016 1:47:00 PM, Continue reading at the source
Alkermes Injectable Technologies In Schizophrenia Will Improve Its Revenue Stream Seeking Alpha - Sep 9, 2016 Despite collaborations with big pharma partners such as Johnson & Johnson (NYSE:JNJ) and AstraZeneca (NYSE:AZN), Alkermes is still trading more than 40% off its 52-week high due to the failure of its two Phase 3 clinical trials of its lead product ... [...]
Fri, Sep 09, 2016 6:33:00 PM, Continue reading at the source
Alkermes Plc (ALKS) Richard Pops on Q2 2016 Results - Earnings Call Transcript Seeking Alpha - Jul 28, 2016 Good morning ladies and gentlemen, and thank you for standing by. Welcome to the Alkermes Conference Call to discuss the Company's Second Quarter Financial Results. Alkermes plc Reports Second Quarter 2016 Financial Results - Business Wire (press release) Alkermes (ALKS) Posts Narrower Q2 Loss, Ups 2016 Outlook - Zacks.com [...]
Thu, Jul 28, 2016 5:03:00 PM, Continue reading at the source
Alkermes Plc (ALKS) Richard Pops on Q1 2016 Results - Earnings Call Transcript Seeking Alpha - Apr 28, 2016 Good morning and welcome to the Alkermes Plc First Quarter 2016 Financial Results Conference. My name is Brandon, and I'll be your operator for today. [...]
Thu, Apr 28, 2016 6:56:00 PM, Continue reading at the source